What 'cartilage growing' actually means after MACI

When patients ask how long MACI cartilage takes to grow, the honest answer involves two separate processes — one happens in a laboratory before surgery even begins, and the other unfolds slowly inside the joint over the following two years.

The first phase starts at the Stage 1 biopsy, during which a small sample of the patient's own chondrocytes is harvested arthroscopically. Those cells are sent to a specialist laboratory — Vericel's facility in Cambridge, Massachusetts, in the case of the branded MACI product — where they are multiplied and seeded onto a thin Type I/III collagen membrane over approximately four to six weeks (Vericel quotes one to two months). The resulting cell-laden scaffold can, if needed, be stored for up to five years before implantation, which gives some flexibility around the timing of Stage 2.

The second phase begins the moment that membrane is fixed into the cartilage defect during Stage 2 surgery. Over the following three to six months, repair tissue gradually fills the lesion — but this early fill is not yet mature, load-bearing cartilage. The tissue continues to consolidate and strengthen for up to two years post-implantation, progressively acquiring the mechanical properties needed for normal joint function.

The practical implication is that the lab phase determines when surgery can proceed; the in-vivo maturation phase determines what the repair tissue ultimately becomes. Conflating them — treating the end of the lab culture period, or even the point of defect fill, as the moment the cartilage is 'done' — significantly underestimates the biological timeline at work.

The four rehabilitation phases and what to expect in each

Recovery unfolds in four overlapping phases, each defined by a dominant biological event in the repair tissue rather than an arbitrary calendar date.

Phase 1 — protection (weeks 0 to 12)

The first priority after surgery is keeping load off the freshly implanted membrane. For the initial six weeks, patients use crutches and a knee brace, with weight-bearing either restricted or eliminated entirely. Between weeks six and twelve, the repair tissue begins anchoring into the surrounding bone and cartilage, and weight-bearing increases in a graded progression under physiotherapy guidance. By 8–12 weeks, most patients have achieved full weight-bearing and can discard the brace — a milestone that marks the close of this protective phase and the transition into active rehabilitation.

Phase 2 — early maturation (months 3–6)

Crutches and brace are gone, but the repair tissue is still consolidating. Patients typically progress to stationary cycling, increasing walking distances, and light resistance work during this window. Driving is usually permitted once adequate quadriceps control is confirmed. The tissue filling the defect is structurally sound enough to bear everyday loads, but it has not yet acquired the full mechanical resilience the joint ultimately demands.

Phase 3 — progressive loading (months 6–9)

As consolidation continues, the programme advances to jogging, agility drills, and sport-specific training. Adherence is particularly important here: advancing intensity too quickly risks overloading repair tissue that has not yet reached full mechanical competence, and setbacks at this stage can lengthen the overall timeline.

Phase 4 — return to unrestricted activity (months 9–12 and beyond)

Unrestricted return to competitive or recreational sport becomes realistic from around nine to twelve months for suitable patients. The contrast with occupational milestones is instructive: some office workers may return to seated work within two weeks of surgery, which underlines that 'recovery' means entirely different things depending on the demands placed on the knee.

Across all four phases, how closely a patient follows the rehabilitation protocol remains the single variable most directly within their control.

When you can return to work, driving, and sport

Driving is where the recovery timetable carries legal as well as clinical weight. The standard in the UK is functional, not calendar-based: patients should not drive until they can perform an emergency stop without pain or delay. The practical timing depends on surgical side and vehicle type. Left-leg surgery combined with an automatic transmission typically allows a return from around six weeks, once quadriceps control has been re-established. Right-leg surgery, or a manual gearbox, generally extends this to 8–12 weeks, since the operated limb must supply full, reliable braking force on demand. Insurers should be notified and clinical clearance obtained before driving resumes — cover may be void if this step is skipped.

The wider point these milestones illustrate is that 'when can I return to normal?' cannot have a single answer. Seated desk work imposes near-zero load on the repair tissue — physiologically a different proposition from the demands of a five-kilometre run, let alone competitive sport. The gap between the earliest occupational return (potentially a fortnight after surgery for those in sedentary roles) and unrestricted athletic activity (nine to twelve months or beyond) reflects the progressive biological maturation the repair tissue must complete, not institutional overcaution.

Patients who frame their expectations around specific activity milestones — work, driving, cycling, running — rather than a single discharge date tend to find the timeline easier to manage, and are less likely to push a healing joint before the underlying tissue is mechanically ready.

What the 10-year evidence says about MACI durability

Two studies published in 2024 now provide the most robust long-term picture available for any cell-based cartilage repair technique. Wang et al. reported on a minimum 10-year follow-up of MACI patients from a randomised controlled trial, finding significant and durable improvements in patient-reported outcomes alongside satisfactory defect fill on MRI — making this the strongest direct long-term evidence yet produced for the procedure. Weishorn et al. added a complementary dataset: graft survival at 96 months (eight years) was 97.2%, with low rates of outright graft failure.

The reoperation picture is similarly reassuring. All-cause reoperation sits at approximately 9% at ten years. Progression to total knee arthroplasty varies across studies — the range runs from 7.4% to 12%, and that spread reflects genuine differences in patient populations, defect characteristics, and follow-up methodology rather than a single reliable figure. Both ends of the range compare favourably with the natural history of untreated full-thickness cartilage lesions.

The comparison with microfracture is most clearly drawn through the SUMMIT trial, which tested the two techniques head-to-head. MACI outperformed microfracture on both pain and function scores at two and five years, particularly for defects of 3 cm² or larger. The mechanistic reason matters here: microfracture stimulates fibrocartilage — a scar-like tissue that is less resilient than native hyaline cartilage and prone to breakdown under repetitive load. In some published series, microfracture survivorship falls below 60% at three years. MACI, by contrast, generates tissue that is histologically closer to hyaline cartilage, which is the likely basis for the more durable functional gains.

One limitation should be stated plainly: data extending beyond ten years and drawn from centres outside specialist surgical programmes remains sparse. The evidence is confident within that window, but it would be inaccurate to present the long-term picture as fully settled.

Which patients get the best outcomes

The 75–93% clinical success figures associated with MACI reflect carefully selected patients — so understanding the selection criteria is inseparable from interpreting the evidence.

Age and defect characteristics define the clearest boundaries. Most published series focus on patients aged 15–55 with isolated, full-thickness chondral lesions of 3–10 cm². The procedure addresses focal damage; it is not appropriate for the diffuse joint-surface loss of advanced or end-stage osteoarthritis, where joint-replacement pathways are the more realistic option. Early intervention for symptomatic focal defects may delay the onset of severe osteoarthritis, but that protective benefit depends on the joint not already being diffusely affected.

Structural factors are equally important. MACI performs best when the knee is mechanically sound — ligamentously stable, with correctable or already-corrected alignment, and free from inflammatory arthritis. Active inflammatory disease continues to attack newly implanted tissue, and uncorrected malalignment concentrates load on the graft. Where significant malalignment exists, a corrective osteotomy before or alongside MACI may be required rather than implantation alone.

Defect location introduces further variation. Current evidence suggests tibiofemoral sites — the femoral condyle and tibial plateau — achieve more consistent long-term results than patellofemoral locations, where the biomechanical environment appears to make durable tissue fill harder to sustain.

One clinically important point often absent from patient-facing information concerns prior marrow-stimulation procedures. Microfracture, in particular, can damage the subchondral bone plate underlying the cartilage surface. That structural change alters the biological environment into which MACI cells are implanted and is a factor surgeons weigh specifically when assessing patients who have already undergone marrow-stimulation work.

Because the published outcome data comes from patients who completed the full rehabilitation programme, the capacity to commit to that process is itself part of what surgeons evaluate at the initial assessment — alongside the structural and biological criteria above.

Getting a specialist assessment in London

Deciding whether MACI is appropriate requires more than reading a timeline or a success-rate figure. Suitability turns on defect size and location, joint alignment, the condition of the subchondral bone, any prior procedures, and the overall health of the surrounding cartilage — none of which can be determined without specialist imaging and direct clinical assessment.

For patients in London and the commuter belt, that assessment is available at the London Cartilage Clinic on Harley Street. Professor Paul Y. F. Lee, who specialises in cartilage restoration, leads assessment and advises on which restorative pathway — whether MACI or an alternative approach — is best matched to the specific anatomy and clinical picture.

If the evidence in this article has raised questions about your own knee, booking a consultation through londoncartilage.com is a straightforward next step.